The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its intramuscular route of administration and low bioavailability are major clinical limitations.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance / Nardone, A.; Weir, H.; Delpuech, O.; Brown, H.; De Angelis, C.; Cataldo, M. L.; Fu, X.; Shea, M. J.; Mitchell, T.; Veeraraghavan, J.; Nagi, C.; Pilling, M.; Rimawi, M. F.; Trivedi, M.; Hilsenbeck, S. G.; Chamness, G. C.; Jeselsohn, R.; Osborne, C. K.; Schiff, R.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 120:3(2019), pp. 331-339. [10.1038/s41416-018-0354-9]
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
De Angelis C.;Cataldo M. L.;
2019
Abstract
The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its intramuscular route of administration and low bioavailability are major clinical limitations.| File | Dimensione | Formato | |
|---|---|---|---|
|
s41416-018-0354-9.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
